Dirk Arnold
迪尔克·阿诺德
MD, PhD
Chief Medical Officer and Head of Oncology首席医疗官兼肿瘤科主任
👥Biography 个人简介
Dirk Arnold is a leading European authority in metastatic colorectal cancer, contributing pivotal data on trifluridine/tipiracil (TAS-102), antiangiogenic therapies, and continuum-of-care strategies. He has been deeply involved in ESMO CRC guideline development and multinational European trials.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Trifluridine/Tipiracil in Europe
Contributed key European data validating trifluridine/tipiracil in refractory CRC, supporting EMA approval and integration into ESMO guidelines for late-line treatment.
Continuum-of-Care CRC Strategy
Championed optimizing bevacizumab continuation beyond progression and sequencing strategies in metastatic CRC, improving outcomes in European real-world cohorts.
Representative Works 代表性著作
Trifluridine/tipiracil versus placebo in patients with heavily treated metastatic colorectal cancer: RECOURSE European sub-analysis
Annals of Oncology (2017)
European sub-analysis confirming OS benefit of TAS-102 in heavily pretreated metastatic CRC patients.
Bevacizumab continuation versus no continuation after first-line chemotherapy in metastatic CRC
Lancet Oncology (2014)
ML18147 trial supporting bevacizumab continuation beyond progression as a clinically meaningful strategy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 迪尔克·阿诺德 的研究动态
Follow Dirk Arnold's research updates
留下邮箱，当我们发布与 Dirk Arnold（Asklepios Tumorzentrum Hamburg）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment